cholinergic drugs

Uploaded on


  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Cholinergic drugs
  • 2.  Also called Cholinomimetic or parasympathomimetic drugs.  Cholinomimetic drugs can elicit some or all of the effects that acetylcholine (ACh) produces.  This class of drugs includes agents that act directly as agonists at cholinoreceptors and agents that act indirectly by inhibiting the enzymatic destruction of endogenous Ach.
  • 3.  The directly acting cholinomimetics can be subdivided into  Agents that exert their effects primarily through stimulation of muscarinic receptors at parasympathetic neuroeffector junctions (parasympathomimetic drugs) and  Agents that stimulate nicotinic receptors in autonomic ganglia and at the neuromuscular junction.
  • 4. Pharmacological Effects of Muscarinic Stimulation  CARDIOVASCULAR SYSTEM:  ACh has four primary effects on the cardiovascular system:  Vasodilation,  Decrease in cardiac rate (the negative chronotropic effect),  Decrease in the rate of conduction in the specialized tissues of the SA and atrioventricular (AV) nodes (the negative dromotropic effect), and  Decrease in the force of cardiac contraction (the negative inotropiceffect).  The last effect is of lesser significance in ventricular than in atrial muscle.  Certain of the above responses can be obscured by baroreceptor and other reflexes that dampen or counteract the direct responses to ACh.
  • 5. GASTROINTESTINAL AND URINARY TRACTS  Although stimulation of vagal input to the gastrointestinal (GI) tract increases tone, amplitude of contraction, and secretory activity of the stomach and intestine.  such responses are inconsistently seen with administered ACh.  Poor perfusion of visceral organs and rapid hydrolysis by plasma butyrylcholinesterase limit access of systemically administered ACh to visceral muscarinic receptors.  Parasympathetic sacral innervation causes detrusor muscle contraction, increased voiding pressure, and ureter peristalsis, but for similar reasons these responses are not evident with administered ACh.
  • 6. MISCELLANEOUS EFFECTS  ACh and its analogs stimulate secretion by all glands that receive parasympathetic innervation, including the lacrimal, tracheobronchial, salivary, and digestive glands.  The effects on the respiratory system, in addition to increased tracheobronchial secretion, include bronchoconstriction and stimulation of the chemoreceptors of the carotid and aortic bodies.  When instilled into the eye, muscarinic agonists produce miosis.
  • 7. Cholinergic drugs  Cholinergic receptor agonists can be divided into two groups:  (1) ACh and several synthetic choline esters, and  (2) The naturally occurring cholinomimetic alkaloids
  • 8. Classification : 1. Choline esters : Acetylcholine, Methacholine, Carbachol, Bethanechol 2. Alkaloids : Muscarine, Pilocarpine, Arecoline
  • 9.  The therapeutic usefulness of ACh is limited by  (1) its lack of selectivity as an agonist for different types of cholinoreceptors and  (2) its rapid degradation by cholinesterases.  These limitations have been circumvented in part by the development of three choline ester derivatives of ACh:  Methacholine ,  Carbachol and  Bethanechol.
  • 10.  Methacholine differs from ACh only in the addition of a methyl group at the beta-carbon of ACh.  This modification greatly increases its selectivity for muscarinic receptors relative to nicotinic receptors.  It renders methacholine resistant to the pseudo-ChE in the plasma and decreases its susceptibility to AChE, thereby increasing its potency and duration of action compared to those of ACh.
  • 11.  Carbachol differs from ACh only in the substitution of a carbamoyl group for the terminal methyl group of ACh.  This substitution makes carbachol completely resistant to degradation by cholinesterases but does not improve its selectivity for muscarinic versus nicotinic receptors.  Bethanechol combines the addition of the methyl group and the substitution of the terminal carbamoyl group, producing a drug that is a selective agonist of muscarinic receptors and is resistant to degradation by cholinesterases.
  • 12. Clinical Uses  Glaucoma  Cholinomimetic drugs are useful for treating glaucoma because they can decrease the resistance to the movement of fluid (aqueous humor) out of the eye, thereby reducing the intraocular pressure.  Surgery of the Eye  Cataract surgery sometimes requires the use of acetylcholine to constrict the pupil rapidly.  Urinary Retention  Postpartum and postoperative non obstructive urinary retention or urinary retention caused by neurogenic bladder. ( Bethanicol )  XEROSTOMIA  Pilocarpine is administered orally in 5–10-mg doses given three times daily for the treatment of xerostomia
  • 13. Adverse Effects  Potentially severe adverse effects can result from systemic administration of cholinomimetic drugs,and none should be administered by intramuscular or intravenous injection.  If significant amounts of these drugs enter the circulation:  Nausea , abdominal cramps, diarrhea, salivation, hypotension with reflex tachycardia, cutaneous vasodilation, sweating, and broncho constriction can result.
  • 14. Indirect Acting Cholinomimetic Drugs Cholinesterase inhibitors:  Reversible Cholinesterase inhibitors:  Physostigmine, neostigmine, pyridostigmine, edrophonium, Tacrine  Irreversible Cholinesterase inhibitors:  Echothiophate, di-isopropylflurophosphate (organo- phosphate compounds, malathion, parathion, diazinon)
  • 15. Basic Pharmacology  Inhibition of AChE potentiates and prolongs the stimulation of cholinoreceptors resulting from ACh released at cholinergic synapses.  These synapses found at the skeletal neuromuscular junction, adrenal medulla, autonomic ganglia, and cholinergic synapses in the CNS.  Inhibition of AChE can increase the stimulation of both muscarinic and nicotinic receptors produced by synaptically released ACh.  several AChE inhibitors also inhibit the pseudo-ChE in plasma. This can permit plasma concentrations of ACh to rise markedly and activate endothelial muscarinic receptors.
  • 16. Physostigmine Action • Inhibits the breakdown of acetylcholine so that it accumulates and has a prolonged effect. Result is generalized cholinergic response, including : - › Miosis. › Increased tone of intestinal and skeletal musculature. › Bronchial and ureteral constriction. › Bradycardia. › Increased salivation. › Lacrimation. › Sweating. › CNS stimulation.
  • 17. Pharmacokinetics  Absorption: Readily absorbed from subcut and IM sites.  Distribution: Widely distributed; crosses the blood-brain barrier.  Half-life: 1–2 hours.
  • 18. Classifications  Therapeutic Classification: antidotes  Pharmacologic Classification: cholinergics, anticholinesterases Availability • Injection: 1 mg/ml in 2-ml ampules
  • 19. Clinical Uses  Myasthenia Gravis  Smooth Muscle Atony  Antimuscarinic Toxicity ( Atropine )  Alzheimer’s Disease (Tacrine, Rivastigmine)  Reversal of Neuromuscular Blockade  Anticholinesterase agents are widely used in anesthesiology to reverse the neuromuscular blockade caused by nondepolarizing muscle relaxants.
  • 20. Adv. Reactions/Side Effects  CNS: seizures , restlessness  EENT: lacrimation, miosis.  Resp: bronchospasm, excess respiratory secretions.  CV: bradycardia, hypotension .  GI: abdominal cramps, diarrhea , nausea, vomiting, excess salivation .